Slideshow
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
-
ARZERRA-ofatumumab-chronic-lymphocytic-leukemia-CL
This slideshow reviews drug information for ARZERRA® (ofatumumab), indicated for chronic lymphocytic leukemia (CLL).
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 17: Clinical Safety and Efficacy
Slide 26: Drug Storage and SupplySlide 28: References
